Search research articles
Contact Us
Filters
Showing results (21-30 of 139) with videos related to
Page
of 14
Sort By:
JAMA
|
March 11, 2024
Spending on Targeted Therapies for Duchenne Muscular Dystrophy
Liam Bendicksen, Aaron S Kesselheim, Benjamin N Rome
Journal of General Internal Medicine
|
September 25, 2021
Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic
Benjamin N Rome, Jerry Avorn, Aaron S Kesselheim
JAMA Network Open
|
September 8, 2025
Medicare Part D Savings Under the Manufacturer Discount Program vs Coverage Gap Discounts
Benjamin N Rome, Katherine R Garrett, Luca Maini
JAMA
|
June 8, 2023
Congress' Misguided Plan to Ban QALYs
Leah Z Rand, Adam Raymakers, Benjamin N Rome
JAMA Health Forum
|
December 13, 2024
Use, Spending, and Prices of Adalimumab Following Biosimilar Competition
Benjamin N Rome, Anushka Bhaskar, Aaron S Kesselheim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 29, 2022
State Laws and Generic Substitution in the Year After New Generic Competition
Benjamin N Rome, Ameet Sarpatwari, Aaron S Kesselheim
The American Journal of Managed Care
|
November 25, 2025
US spending on high-revenue rare disease drugs in 2022
Helen Mooney, Aaron S Kesselheim, Benjamin N Rome
The American Journal of Managed Care
|
March 16, 2026
Biosimilar interchangeability and substitution in the US: what comes next?
Benjamin N Rome, Anushka Bhaskar, Aaron S Kesselheim
Journal of General Internal Medicine
|
April 27, 2026
Prescription Drugs Affected by an Expanded Rare Disease Carve-Out from Medicare Price Negotiation
Benjamin N Rome, Helen Mooney, Aaron S Kesselheim
JAMA
|
March 10, 2025
Engaging Pharmacists in Strategies for Navigating Prescription Drug Costs-Reply
Hussain S Lalani, Catherine S Hwang, Benjamin N Rome
Page
of 14
Search research articles
Search
Showing results (21-30 of 139) with videos related to
Sort By:
Page
of 14
JAMA
|
March 11, 2024
Spending on Targeted Therapies for Duchenne Muscular Dystrophy
Liam Bendicksen, Aaron S Kesselheim, Benjamin N Rome
Journal of General Internal Medicine
|
September 25, 2021
Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic
Benjamin N Rome, Jerry Avorn, Aaron S Kesselheim
JAMA Network Open
|
September 8, 2025
Medicare Part D Savings Under the Manufacturer Discount Program vs Coverage Gap Discounts
Benjamin N Rome, Katherine R Garrett, Luca Maini
JAMA
|
June 8, 2023
Congress' Misguided Plan to Ban QALYs
Leah Z Rand, Adam Raymakers, Benjamin N Rome
JAMA Health Forum
|
December 13, 2024
Use, Spending, and Prices of Adalimumab Following Biosimilar Competition
Benjamin N Rome, Anushka Bhaskar, Aaron S Kesselheim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 29, 2022
State Laws and Generic Substitution in the Year After New Generic Competition
Benjamin N Rome, Ameet Sarpatwari, Aaron S Kesselheim
The American Journal of Managed Care
|
November 25, 2025
US spending on high-revenue rare disease drugs in 2022
Helen Mooney, Aaron S Kesselheim, Benjamin N Rome
The American Journal of Managed Care
|
March 16, 2026
Biosimilar interchangeability and substitution in the US: what comes next?
Benjamin N Rome, Anushka Bhaskar, Aaron S Kesselheim
Journal of General Internal Medicine
|
April 27, 2026
Prescription Drugs Affected by an Expanded Rare Disease Carve-Out from Medicare Price Negotiation
Benjamin N Rome, Helen Mooney, Aaron S Kesselheim
JAMA
|
March 10, 2025
Engaging Pharmacists in Strategies for Navigating Prescription Drug Costs-Reply
Hussain S Lalani, Catherine S Hwang, Benjamin N Rome
Page
of 14